In a recently employed approach, MYC expression is blocked by impairing a BET bromodomain protein, a strategy that has proved effective both in vitro and in xenograft models in a range of hematological neoplasms, including Burkitt lymphoma [51–53]. Here, MYC is linked to hematopoietic and lymphoid system neoplasm.